Methylenetetrahydrofolate reductase C677T genotype and PD

Annals of Neurology

Volumn 57, Issue 6, 2005, Pages 927-930

  De Lau, Lonneke M L ^a   Koudstaal, Peter J ^a   Van Meurs, Joyce B J ^a   Uitterlinden, André G ^a   Hofman, Albert ^a   Breteler, Monique M B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; NERVE CELL NECROSIS; NEUROTOXICITY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE; POINT MUTATION; PROSPECTIVE STUDIES; SMOKING;

EID: 20444366135     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20509     Document Type: Article

References (16)

1. Greenamyre JT, Hastings TG. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004;304: 1120-1122.
2. Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80:101-110.
3. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20: 6920-6926.
4. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999;354:126-127.
5. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40: 225-227.
6. Yasui K, Kowa H, Nakaso K, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-440.
7. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003;26:137-146.
8. Brown KS, Kiuijtmans LA, Young IS, et al. The 5,10- methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteine. Atherosclerosis 2004;174:315-322.
9. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10: 111-113.
10. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-422.
11. de Lau LM, Giesbergen PC, de Rijk MC, et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240-1244.
12. Fahn SER, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S MC, Calne DB, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
13. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96: 1432-1437.
14. Husemoen LL, Thomsen TF, Fenger M, Jorgensen T. Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype. Inter99 (7). Eur J Clin Nutr 2004;58:1142-1150.
15. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004;27:561-568.
16. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002;70:694-702.